Elixirgen Therapeutics, Inc.
This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).
Patients who received EXG34217 treatment and had at least one follow-up visit (Month 1, 3, 6, or 12) in Study EXG-US-01 will be eligible for this rollover study. Patient will sign a consent form prior to any study related procedure. This study is to add additional follow-up assessments up to 6 years after EXG34217 treatment. This study does not have additional intervention. Additional visits will be every 6 months in the first 3 years and once a year for two years.
Inclusion Criteria: 1. Signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of, and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed consent must be obtained from the subject prior to initiating procedures. 2. Have completed the 12-month visit of Study EXG-US-01. Exclusion Criteria: \-
Single infusion
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.